News & Events

EpiEndo Pharmaceuticals has received an INN (International Non-proprietary Name or generic name) from the World Health Organisation for its lead clinal drug candidate. EP395 has received the INN name glasmacinal.

Maria Bech, CEO of EpiEndo Pharmaceuticals will be presenting at the YAFO Capital Access China Partnering Forum on 24, 25 and 27 September 2024.

EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic respiratory diseases, will be presenting three posters showcasing clinical and preclinical data on lead asset EP395 in chronic respiratory diseases at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria.

REYKJAVIK, ICELAND – 5 June 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has posted a video of CEO Maria Bech speech at BioStock Global Forum from 29th of May.

REYKJAVIK, ICELAND & BERN, SWITZERLAND – 4 June 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’), a clinical-stage biopharmaceutical company leading in epithelial biology, and AlveoliX, a pioneer in organ-on-chip technology, announce significant milestones in their collaboration to revolutionize ulcerative colitis (UC) treatment. The EpicoliX Project is supported by a grant of ~EUR1.4M from the Eureka Eurostars funding program, the Icelandic Technology Development Fund, and Innosuisse in Switzerland.

REYKJAVIK, ICELAND – 7 May 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has contributed to a book chapter in Macrolides as Immunomodulatory Agents, published in January.

REYKJAVIK, ICELAND – 10 April 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

EpiEndo Pharmaceuticals has announced the recent appointments of Professor Bartolome Celli and Professor Fernando J. Martinez to its Scientific Advisory Board.